evp head ehler step limelight
wedbush view chang outlook share earlier morn
announc evp head michael ehler leav compani
new opportun chief medic offic dr al sandrock assum dr ehler
role lead develop effort posit dr sandrock held
past given lengthi tenur assum minimal/no disrupt
front forese move point time arriv
ahead numer late-stag pipelin readout slate
howev dr ehler assum early-stag leadership role limelight
appreci uniqu opportun bigger pictur see
investor continu focus later-stag program
overal strateg outlook remain neutral rate
head michael ehler leav announc dr michael ehler
evp head leav compani effect see pr
current chief medic offic al sandrock assum dr ehler current role
recal dr ehler join also recal dr sandrock long-
term fixtur feel keep effort track minim
head limelight concurr announc
ventur capit firm appl partner announc dr ehler becom
ventur partner firm new chief scientif offic well
ceo gene therapi start-up limelight overal move appear
quit differ career move step toward ventur
mean check-in compani note
remain confid pipelin potenti anticip littl chang
strategi remind us dr sandrock hold long track record
industri specif best equip handl role
interim basi go forward recal dr sandrock previous
led develop effort past admittedli time seem
bit unexpect pipelin featur nine late-stag readout
next month howev would seem uniqu opportun
dr ehler
remain neutral rate pipelin arguabl import
futur success point see early-stag effort quit
expans major hole view later-stag asset
remain readout could help address gap near-term
one phase passport data psp gosuranemab phase
system lupu erythematosu data late overal outlook
remain unchang
wedbush secur seek busi compani cover
research report thu investor awar firm may
conflict interest could affect object report investor
consid report singl factor make invest decis
pleas see page report analyst certif import
target deriv ep estim discount back discount peer
consensu ep due compani matur product portfolio
risk attain price rate
clinic data emerg clinic studi significantli impact share either posit neg direct
regulatori employ acceler strategi gain approv regul may requir addit data could alter
requir approv necessit addit longer studi failur gain product label lack certain featur could
limit abil gain traction market
commerci failur execut commerci inabl meet/exce expect impact share
competit updat competitor may posit neg impact share relev competitor includ compani
novarti roch sanofi lilli teva sandoz competitor like emerg time
generic/biosimilar entri new gener biosimilar agent may put pressur exist market product
limit compani abil realiz increas price
laura chico certifi view express report accur reflect person opinion
directli indirectli receiv compens payment connect specif recommend view contain
report
outperform expect total return stock outperform rel median total return analyst analyst
team coverag univers next month
neutral expect total return stock perform in-lin median total return analyst analyst team
coverag univers next month
under-perform expect total return stock under-perform rel median total return analyst
analyst team coverag univers next month
invest rate base expect perform stock base anticip total return price target rel
stock analyst coverag univers analyst team coverag
octob
octob
distribut rate requir finra rule howev ws stock rate outperform neutral under-perform
close conform buy hold sell respect pleas note howev definit ws stock rate
rel basi
analyst respons prepar research report receiv compens base specif invest bank activ
analyst receiv compens base upon variou factor includ ws total revenu portion gener
ws invest bank activ
ws make market secur inc
inc rate histori
power bluematrix
wedbush disclosur price chart updat within first fifteen day new calendar quarter per finra regul price
chart compani intiat upon current quarter rate target price chang occur current quarter
display follow quarter addit inform recommend secur avail request
disclosur inform regard histor rate price target avail research disclosur
ws chang rate system strong buy/ buy/ hold/ sell outperform/ neutral/ under-perform juli
applic disclosur inform also avail upon request contact lesli lippai research depart
email busi conduct depart may also submit written
request follow busi conduct depart wilshir blvd lo angel ca
inform herein base sourc consid reliabl accuraci guarante inform contain
herein represent corpor recommend made herein base privileg inform
inform intend reli upon complet record analysi neither offer solicit
offer sell buy secur mention herein firm wedbush secur offic employe member
famili one discretionari advisori account may posit secur discuss herein
relat secur may make time time purchas sale thereof open market otherwis inform
express opinion contain herein subject chang without notic herein mention secur may
sold bought custom princip basi firm addit inform respect inform contain
herein may obtain upon request
wedbush secur seek busi compani cover research report thu investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis pleas see page report analyst certif import
